371 related articles for article (PubMed ID: 25436773)
1. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
[TBL] [Abstract][Full Text] [Related]
2. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis.
Yin Y; Zhang J; Dong D; Liu S; Guo Q; Song X; Li G; Fu L; Xu J; Chen W
Vaccine; 2008 Oct; 26(46):5814-21. PubMed ID: 18786589
[TBL] [Abstract][Full Text] [Related]
3. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
4. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
Xie Y; Sun HX; Li D
Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
[TBL] [Abstract][Full Text] [Related]
5. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
6. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine.
Fakharzadeh S; Kalanaky S; Hafizi M; Goya MM; Masoumi Z; Namaki S; Shakeri N; Abbasi M; Mahdavi M; Nazaran MH
Vaccine; 2013 May; 31(22):2591-7. PubMed ID: 23583463
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
Sani MZ; Bargahi A; Momenzadeh N; Dehghani P; Moghadam MV; Maleki SJ; Nabipour I; Shirkani A; Akhtari J; Hesamizadeh K; Heidari S; Omrani F; Akbarzadeh S; Mohammadi M
Appl Microbiol Biotechnol; 2021 Jan; 105(1):77-91. PubMed ID: 33215260
[TBL] [Abstract][Full Text] [Related]
8. Development of HBc virus-like particles as modular nanocarrier by intein-mediated trans-splicing.
Wang Z; Tang S; Yue N; Qian Z; Zhou S
Biochem Biophys Res Commun; 2021 Jan; 534():891-895. PubMed ID: 33213839
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
10. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.
Moon SH; Shin EC; Noh YW; Lim YT
Vaccine; 2015 Sep; 33(38):4762-9. PubMed ID: 26271830
[TBL] [Abstract][Full Text] [Related]
12. Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent
Hou Y; Yan T; Cao H; Liu P; Zheng K; Li Z; Deng Q; Hu S
Int J Nanomedicine; 2019; 14():6601-6613. PubMed ID: 31496701
[TBL] [Abstract][Full Text] [Related]
13. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
14. Effects of various adjuvants and a viral infection on the antibody specificity toward native or cryptic epitopes of a protein antigen.
Gómez KA; Longhi SA; Marino VJ; Mathieu PA; Loureiro ME; Coutelier JP; Roguin LP; Retegui LA
Scand J Immunol; 2003 Feb; 57(2):144-50. PubMed ID: 12588660
[TBL] [Abstract][Full Text] [Related]
15. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
[TBL] [Abstract][Full Text] [Related]
16. Non-Conjugated Chitosan-Based Nanoparticles to Proteic Antigens Elicit Similar Humoral Immune Responses to Those Obtained with Alum.
Izaguirre-Hernández IY; Mellado-Sánchez G; Mondragón-Vásquez K; Thomas-Dupont P; Sánchez-Vargas LA; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Vivanco-Cid H
J Nanosci Nanotechnol; 2017 Jan; 17(1):846-52. PubMed ID: 29634187
[TBL] [Abstract][Full Text] [Related]
17. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
18. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.
Huang Z; Santi L; LePore K; Kilbourne J; Arntzen CJ; Mason HS
Vaccine; 2006 Mar; 24(14):2506-13. PubMed ID: 16417953
[TBL] [Abstract][Full Text] [Related]
19. Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles.
Sahu KK; Pandey RS
Int Immunopharmacol; 2016 Oct; 39():343-352. PubMed ID: 27526270
[TBL] [Abstract][Full Text] [Related]
20. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties.
Wang T; Jiang H; Zhao Q; Wang S; Zou M; Cheng G
Int J Pharm; 2012 Oct; 436(1-2):351-8. PubMed ID: 22721849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
